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Host defense against viral infection is extremely com­
plex and includes both humoral and cellular immune 
mechanisms. This contribution examines the mecha­
nisms by which antibody (Ab) and the complement (C) 
system, major constituents of the humoral immune sys­
tem, inactivate viruses and block viral maturation in 
virus-infected cells in vitro. 
Ab and C may neutralize viruses by envelopment in a 
coating of protein, by aggregation by lysis, or by facili­
tating interactions with various effector cells. Ab and C 
molecules deposited on the surfaces of viruses may phys­
ically interfere with the ability of the virus to infect a 
potentially susceptible cell. This appears to be the most 
common mechanism by which Ab and C neutralize vi­
ruses. In rare instances, Ab and/or C may aggregate 
viruses; aggregation reduces the net number of infec­
tious particles and thus is manifest as neutralization. C 
may lyse enveloped viruses, resulting in irreversible 
viral inactivation. However, this does not appear to be 
a major mechanism of viral neutralization. Finally, the 
Fc portions of bound Ab molecules as well as bound C 
molecules may interact with effector cells with specific 
receptors for these factors and thereby facilitate viral 
destruction. 
In regard to virus-infected cells, the deposition of Ab 
or C on the cell surface may prevent the maturation or 
release of viral particles and alter normal cellular func­
tions. Ab and C may also lyse virus-infected cells, ab­
ruptly stopping further viral maturation. Such lytic 
events require only the F(ab'h portion of the Ab mole­
cule and proceed via activation of the alternative C 
pathway. Effector cells may also interact with Ab and/ 
or C molecules deposited on virus-infected cells, leading 
to cytotoxic reactions and/or ingestion depending on the 
type of effector cell involved. 
The activated C system has the ability to produce an 
acute inflammatory response leading to alterations in 
vessel permeability, edema, changes in smooth-muscle 
contractility, and the influx of leukocytes. Such inflam­
matory responses occurring in tissues, including the 
skin, as a result of C activation not only retard the 
spread of the infection and facilitate the destruction of 
the infectious agent, but also in all likelihood damage 
normal tissues in the vicinity. In addition, C activation 
in tissues also has the ability to stimulate arachidonic 
acid metabolism and induce the release of histamine and 
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other mediators as well as pyrogens from appropriate 
cell types. A number of the systemic symptoms charac­
teristic of viral infections, such as headaches, myalgias, 
and fever, likely result from such processes. 
Viruses are major human pathogens responsible for a number 
of acute and chronic infectious diseases. They have the ability 
to replicate in human cells and thereby to serve as a persistent 
or increasing antigenic challenge. Furthermore, by several dif­
ferent mechanisms, certain viruses, particularly those respon­
sible for cutaneous disease, have the potential to become latent 
in cells and reemerge at a subsequent time to directly or 
indirectly produce disease. Some viruses alter genetic structure 
to generate an ever-changing panorama of antigens, while 
others integrate into the genome and may be passed from 
generation to generation. Because of these many features, it is 
likely that viruses are largely responsible for driving the im­
mune system to ever greater complexity through evolution. 
Host defense against virus infection includes physical bar­
riers and various substances with antiviral potential and the 
constituents of the highly complex, finely tuned immunologic 
network. By historical convention, immunologic mechanisms 
are divided into humoral and cellular arms, with the former 
including the actions of Ab and C and the latter including 
cellular immunity and various cellular effector systems. This 
paper focuses exclusively on the role of Ab and the C system 
functioning individually and cooperatively to eliminate viruses 
and virus-infected cells. Although not to be considered in detail 
here, it is important to emphasize that these humoral immu­
nologic mechanisms do not operate alone in vivo, but rather in 
a coordinated, integrated manner with other immunologic de­
fense mechanisms, which include the actions of cytotoxic T 
cells, killer cells, natural killer cells, monocytes, macrophages, 
and polymorphonuclear leukocytes. 
Although the constituents of the humoral and cellular im­
mune systems are found in the circulation, most of their actions 
occur in tissues. The modest amounts of the proteins and cells 
of the immune system normally present in tissues increase 
dramatically during infection or injury. These agents accumu­
late in injured tissue as a consequence of a number of interre­
lated processes, including increased permeability of blood ves­
sels, alterations in smooth-muscle contractility, the actions of 
leukotactic factors and other cytokines, and the de novo pres­
ence of opsonins and altered C proteins that interact with 
receptors located on the surfaces of the cells of the immune 
system. These effects can also occur in the skin with injury, 
particularly as exemplified in the inflammatory response. In 
certain diseases as well, Ab and C are deposited between the 
dermis and the epidermis in the absence of inflammation. 
COMPLEMENT ACTIVATION PATHWAYS AND 
BIOLOGY 
Complement is an effector system responsible for a number 
of biological activities. The constituents of the system are 20 
immunologically distinct plasma proteins termed components 
or factors. Together, the C proteins represent a significant 
proportion of the plasma proteins, since their cumulative con­
centration exceeds 300 mg/dl. C activation, a prerequisite for 
biological activity, triggers an orderly, sequential, and carefully 
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FIG 1. Pathways and biology of the C 
system. (Reprinted with permission from 
/33].) 
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regulated series of interactions between C proteins and the 
virus or other activator. The reactions involving the C factors 
and the activators can be grouped into several units, each of 
which involves several of the C proteins (Fig 1). There are two 
activation pathways, termed the classical and the alternative or 
properdin pathways, respectively [1-4]. Although each pathway 
comprises the reaction steps of several different C proteins, 
there are overall similarities in the basic mechanisms involved. 
Both the classical and the alternative pathways consist of, and 
are driven by, a series of enzyme-substrate reactions, with the 
enzymes involved in these interactions being generally formed 
from inactive C precursor molecules by limited proteolytic 
cleavage by other C enzymes. A second similarity is that each 
reaction pathway, as well as the terminal-membrane attack 
pathway, involves the systematic formation of large multimo­
lecular assemblies of several different C proteins, as noted 
below. The enzyme-substrate interactions and the protein­
protein complexes exhibit a very high order of specificity in 
that no other C component can substitute for the enzyme, 
substrate, or tbe interacting proteins involved in tbese various 
interactions. The C cleavage fragments generated by limited 
proteolysis and the protein-protein complexes possess various 
functional activities that are responsible for many of the bio­
logical activities of the activated C system. The classical and 
the alternative pathways are independently triggered by certain 
agents. The particular properties that endow a substance with 
the ability to trigger one or the other or both pathways are not 
yet understood. Both pathways may also be triggered in the 
complete absence of Ab by a number of the substances of 
extremely diverse chemical and physical composition [2,5]. In 
the case of the classical pathway, these include polyanions, 
certain cellular membranes, lipid A of lipopolysaccharides, and 
several viruses, among a number of other substances. In the 
case of the alternative pathway, non-Ab-dependent activators 
include several cell types, bacteria, complex polysaccharides, 
certain viruses, and virus-infected cells, among other sub­
stances. 
As has been known for some years, the classical pathway is 
readily triggered by IgG- and IgM-containing immune com­
plexes. This is equally true of Ab in combination with viruses 
and with viral antigens on the surfaces of virus-infected cells, 
both of which behave as typical immune complexes. More 
recently, it has become evident that antibody also activates or 
potentiates alternative-pathway activation in a number of sys­
tems. This is particularly true of cells infected with a number 
of viruses. 
With activation of the classical C pathway, the first compo­
nent, C1, is converted into an enzyme that cleaves C4 and C2 
and the next two reacting components (Fig 1). These proteins 
interact with each other to form a protein-protein complex, 
C4b,2a, that is a de novo enzyme able to cleave the next reacting 
factor, C3. With cleavage of C3, yet another enzyme is formed, 
C4b,2a,3b, that cleaves C5. 
The alternative C pathway, originally described as the pro­
perdin system, involves a series of protein-protein interactions 
that leads to the formation on the activator surface of an 
enzyme, C3b,P,Bb, that contains properdin (P) and cleaved C3 
and factor B (B) (Fig 1). The C3b,P,Bb enzyme has the ability 
to cleave C5. On activators, this enzyme is protected by an 
unknown mechanism from inactivation by control proteins, 
whereas on the surface of nonactivators, the enzyme is rapidly 
degraded. 
Complement activation, regardless of the pathway involved, 
leads to the deposition of C components on the surface of the 
activator. Substantial numbers of molecules of certain of the C 
components, notably C1q, C4b, and C3b, may become bound 
to the activator as a consequence of C activation. 
The membrane attack pathway is set in motion after limited 
proteolysis of C5 by the C5 cleaving enzymes of either the 
classical or the alternative C pathways. Following C5 hydroly­
sis, the remaining proteins, C6, C7, C8, and C9, interact with 
the cleaved C5 molecule to form a large multi molecular com­
plex, C5b-9, termed the membrane attack complex. This protein­
protein complex has the transient ability, immediately after 
formation, to disrupt lipid-containing membranes, including 
those of viruses and virus-infected cells, and thereby to produce 
lysis. It is responsible for the cytolytic activity of the C system. 
The activities of the C pathways are regulated by a group of 
proteins and functional-site inhibitors that regulates the acti­
vation of both C pathways. C1 inhibitor, C4-binding protein, 
and factor I modulate the activity of the classical pathway, 
while factors H and I regulate the activity of the alternative 
pathway. S protein controls the activity of the assembling C5b-
9 membrane attack complex. 
The biological activities produced by the activated C system 
are extremely diverse. These biological reactions are the direct 
consequence of the protein-protein complexes and enzyme­
substrate interactions characteristic of C-activation processes. 
Most familiar is the ability of the C5b-9 complex to disrupt 
lipid bilayer membranes and thereby to mediate the lysis of 
numerous types of cells, including viruses and virus-infected 
cells. Separate from such direct cytotoxic and cytolytic effects, 
July 1984 ANTIBODY AND COMPLEMENT IN THE CONTROL OF VIRAL INFECTIONS 1238 
bound C components, primarily C4b and C3b, can interact with 
effector cells that have specific receptors for these components. 
Such cells include lymphocytes, neutrophils, monocytes, mac­
rophages, and mast cells. In this type of reaction, C3b and C4b 
cross-link the virus, virus-infected cell, or other target cell on 
which the C reaction sequence is occurring with the effector 
cell. Depending on the responding effector cell involved, bound 
C3b and C4b may facilitate cytotoxicity, aid in phagocytosis, 
stimulate oxidative metabolism, trigger enzyme release, or po­
tentially modulate immunologic responses and immune reac­
tions (Fig 1). Certain other biological actions stem from the 
activities of C3a, C4a, and C5a, the smaller cleavage products 
of C3, C4, and C5, respectively. These hormone-like peptides, 
termed anaphalatoxins, have potent actions on several kinds of 
leukocytes and on smooth muscle. They trigger the release of 
histamine and other secondary mediators, contract smooth 
muscle, and initiate other reactions; C5a is in addition chemo­
tactic and thus stimulates the directed migration of leukocytes 
into the area of C activation. Although C is able to mediate 
numerous biological reactions in vitro, as indicated above and 
in Fig 1, the more important in vivo roles of C in diseases, 
including those of viral origin, are probably related to the ability 
of the system to produce an acute inflammatory response and, 
second, to aid in the direct (via lysis or other destructive action) 
or indirect (via the opsonic and phagocytosis-promoting role of 
the C system) inactivation of pathogens. Thus C activation in 
a localized environment leads to changes in capillary permea­
bility, edema, and alterations in vessel contractility and induces 
the directed migration of leukocytes into the area and the 
release of secondary mediators that further amplify these 
events. These reactions together comprise an acute inflamma­
tory response that retards dissemination of the infectious pro­
cess. The second probable major role of the C system stems 
from the ability of the C system to aid in the destruction of 
infectious agents, including viruses and virus-infected cells. By 
several mechanisms, C may neutralize viruses, and C can also 
lyse virus-infected cells, as discussed below. In addition, several 
of the C components function as opsonins and thus may aid in 
phagocytosis of virus-infected cells and, potentially, viruses. 
Phagocytic cells induced to migrate into an area of C activation 
by C5a become fixed to C3b and C4b attached to the pathogen 
surface. Facilitated phagocytosis and/or killing of the target 
cell follows. 
VIRUSES AND VIRUS-INFECTED CELLS AS 
IMMUNOGENS, COMPLEMENT ACTIVATORS, AND 
TARGETS FOR IMMUNOLOGIC RESPONSES 
There is evidence for natural humoral and cellular immunity 
to viruses and virus-infected cells operative on first exposure 
[6]. Natural humoral immunity includes C and nonelicited, 
cross-reacting, or natural Ab. Certain viruses directly activate 
either the classical or alternative C pathways in the absence of 
Ab. In this type of reaction, the C system fulfills the recognition 
role normally associated with Ab. Such a mechanism may 
represent a natural surveillance function for the C system. 
Direct activators of the classical pathway include retroviruses, 
which directly and very efficiently activate purified Cl [7]. In 
this instance, activation is initiated by the binding of Cl, via 
the Clq subunit of this component, to the virus. The viral 
activator has been isolated and identified as the p15E envelope 
protein of this class of viruses [8]. Classical-pathway activation 
has been observed with many different retroviruses [9]. Since 
Sindbis [10] and Newcastle disease [11] viruses activate the 
classical pathway in human agammaglobulinemic sera and in 
specifically absorbed sera, they most likely also directly activate 
the classical pathway. 
Direct activators of the alternative pathway include Sindbis 
[10] and Epstein-Barr viruses (EBV), which trigger this path­
way in agammaglobulinemic and/or absorbed human sera 
[12,13]. Studies with physiologic concentrations of the purified 
proteins of the alternative C pathway have confirmed the ability 
of EBV to activate the alternative pathway and have shown 
that this activation does not require Ab [12,13]. 
Certain virus-infected cells also have the ability to activate 
the complement system in the absence of Ab. In the two virus 
systems thus far examined in detail, measles [14] and EBV 
[15], infected human cells have been found to have this prop­
erty. The lack of an Ab requirement for C activation by measles 
virus-infected cells has been verified by studies with mixtures 
of the purified proteins of the alternative pathway [14]. 
Natural humoral immunity also includes Ab originally stim­
ulated by other agents that may cross-react with viral glycopro­
teins or other exposed viral structures. For example, sera from 
individuals lacking conventional antibodies and thus apparent 
humoral immunity to EBV contain low levels of IgG antibody 
directed against another member of the herpesvirus family, 
herpes simplex 1, that cross-reacts with purified EBV [16]. 
This Ab triggers classical-pathway activation. Another example 
is a cross-reacting IgG antibody found in normal human sera 
that reacts with the hemagglutinin of type HINI influenza 
virus. The immune complex thus formed activates the classical 
C pathway [17]. 
Viral structures are antigenic and induce the formation of 
specific Ab. Such Ab attached to accessible viral antigens 
located on the surface of viruses and virus-infected cells may 
activate C [18]. Complement activation by virus-Ab complexes 
is usually via the classical pathway, but certain instances of 
alternative pathway activation by Ab-sensitized viruses have 
been reported [17]. In contrast, most virus-infected cells inter­
act with the alternative C pathway [6,19-21]. These studies 
and the unusual role of the alternative pathway are further 
discussed below. 
Complement activation by either pathway and regardless of 
whether triggered directly or via antibody leads to the deposi­
tion of C proteins on the activator. Complement components 
of the appropriate activation pathway, as well as of the mem­
brane attack pathway, have been demonstrated on the surfaces 
of viruses and virus-infected cells following C activation [6,18]. 
In the case of virus-infected cells, C components become de­
posited on areas of the cell membrane directly overlying viral 
nucleocapsids, and adjacent portions of the membrane are free 
of C components [22]. Thus C activation and the resulting C­
component deposition is specifically restricted to the C activa­
tor and the immediately adjacent area. The physical presence 
of Ab and C molecules on the surfaces of viruses and virus­
infected cells has a number of direct consequences, as consid­
ered below. In addition, the presence of antibody and comple­
ment components on viruses and virus-infected cells may also 
facilitate interactions with various effector cells. Such reactions 
may lead to ingestion by phagocytic cells with Fc receptors or 
antibody-dependent cellular cytotoxicity (ADCC) mediated by 
lymphocytes and certain phagocytic cells interacting, via Fc 
receptors, with virus-infected cells [20]. Although not yet in­
vestigated in virus systems, similar comments probably pertain 
to C3b and C4b, which become bound to the virus or virus­
infected cells as a consequence of C activation. B-lymphocytes, 
monocytes, macrophages, and polymorphonuclear leukocytes 
have C receptors. These resulting interactions of effector cells 
with bound activated C components may also facilitate ADCC 
as well as ingestion. 
Structural glycoproteins and other virus-induced changes in 
the membranes of virus-infected cells are undoubtedly respon­
sible for direct C triggering and for the induction of humoral 
and cellular immune responses. Immune responses to nonex­
posed structures, although frequently measured in the clinical 
laboratory and extensively used in diagnosis and in monitoring 
the course of viral diseases, are not directly relevant to host 
defense against viral infection and replication. 
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ANTIBODY- AND COMPLEMENT-DEPENDENT 
VIRAL NEUTRALIZATION 
Antibody- and complement-dependent interactions with iso­
lated viruses frequently lead to viral neutralization. There are 
three principal mechanisms by which Ab and/or C can directlv 
neutralize viruses. These are aggregation, C-dependent lysi� , 
and envelopment with a blanket of Ab and/or C protein. 
Both enveloped and nonenveloped viruses have multiple 
copIes of proteins on their surfaces and may accordingly be 
aggregated by multivalent Ab directed against such proteins. 
Antibody-dependent aggregation has been observed for many 
enveloped and nonenveloped viruses [18,20,23,24]. Aggregation 
has generally been ascertained by demonstrating an increased 
sedimentation rate in zonal ultracentrifugation studies with 
radio labeled virus and/or Ab. Although aggregation does not 
lead to the irreversible viral inactivation, it does produce ap­
parent neutralization by reducing the net number of infectious 
units. Depending on the virus involved, relatively few molecules 
of antibody may be required to produce aggregation. For ex­
ample, only two Ab molecules per virion were required to 
aggregate polyoma virus, a nonenveloped DNA-containing vi­
rus [2:l]. In the same studies, approximately 20 molecules of 
Ab per virion led to marked viral neutralization. 
Complement-dependent viral aggregation can only occur via 
C1q-dependent cross-linking [2:3] or in the rare instances in 
which viral particles possess the abilitv to interact with acti­
vated C components. The latter has thus far been observed 
with p�lyoma virus, which becomes aggregated upon comple­
tIOn 01 the reaction sequence through the C:3 step (Table I). 
Although not yet proved, it is likely that polyoma virus pos­
sesses a C:3b-binding structure. In this context, C3b attached 
TABLE 1. Complement-dependent neutralization of polyoma virusa 
Reagents added to 
polyoma virus antibody 
None 
Human serum 
Human C1q 
Human ('1 
Human C1, ('4, C2 
Human C1, C4, C2, C3 
a Adapted from [2:\]. 
Percent 
neutralization 
o 
80 
60 
o 
o 
84 
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to one viral particle as a consequence of C activation by the 
virus- Ab complex could interact with C3b-binding structures 
on an adjacent viral particle, thus producing aggregation [23]. 
Ant lbody- and complement-dependent aggregations are 
prob�bly uncommon mechanisms of viral neutralization [6]. 
DespIte the requirement for relatively few molecules to produce 
Ab-dependent viral aggregation, the occurrence and extent of 
Ab-dependent aggregation are influenced by numerous physical 
and steric considerations related to the density, location dis­
tribution, and exposure of the antigenic sites and the co�cen· 
tration, class, and affinity of the Ab. Furthermore, Ab-depend­
ent aggregation requires relatively high concentrations of the 
reactants; agglutination is precluded if the viral particles are 
either saturated with Ab or in great excess over Ab. Similar 
considerations probably pertain to C-dependent aggregation. 
Most, and probably all, enveloped viruses are potentially 
susceptible to C-mediated lysis. Complement-dependent lvsis 
of numerous viruses has been demonstrated [6,18,20]. The 
techniques utilized to demonstrate viral lysis include electron 
microscopy. In this approach, as studied with lymphocytic 
choriomeningitis virus [25] and with EBV [26], there is thick· 
ening of the viral envelope due to insertion of the C5b-9 
complexes into the lipid bilayer, progressive separation of the 
envelope from the nucleocapsid, and varying degrees of disin­
tegration of the nucleocapsid (Fig 2). The typical circular 
lesions characteristic of the action of the membrane attack 
complex on lipid-containing membranes are also visible bv 
negative staining. Viral lysis has also been demonstrated b� 
showing the release of viral nucleic acids (Fig 3) or intern;l 
constituents, including enzymes and antigens [7,8,18]. 
Complement-dependent lysis, although leading to irreversi­
ble viral inactivation, is not likely to be a biologically important 
mechanism of viral neutralization. First, the phenomenon is 
restricted to enveloped viruses because of the requirement for 
insertion of the C5b-9 complex into a lipid-containing mem­
brane for the C system to produce lysis. In addition, the bilayer 
of the viral envelope must be accessible to insertion of the C5b-
9 complex. Such access may be impeded in many viruses 
because of the density of envelope proteins. Second, a number 
of viruses, although susceptible to C-mediated lysis, are fully 
neutralized after completion of only a portion of the comple· 
ment reaction sequence, as described below. Third, it appears 
that a very potent activation stimulus is required to trigger the 
. 
FIG 2. Electron microscopic examination of interactions of EBV with Ab and C. EBV was examined alone (left) and after interaction with 
Immune IgG Ab {center} or WIth Immune IgG Ab and C (rillht). (Reprinted with permission from [34].) 
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FIG 3. (Left) Dextran density-gradient ultracentrifugal analysis of 
3H-Iabeled EBV. (Right) 'H-labeled EBV incubated with immune IgG­
Ab, C, and DNase. (Reprinted with permission from !34j.) 
TABLE II. Complement-dependent lysis of murine leukemia virusa 
Reagent added to purified 
Moloney leukemia virus 
Picomoles of 'H -TMP 
polymerizedb 
a* b* 
Normal human serum 2.17 1.55 
C2-deficient serum 0.10 
C4-depleted serum 0.02 
C8-deficient serum 0.17 
Factor B-depleted human serum 0.83 
Control (detergent) 3.37 --- --_ ... -- ---,- ---- ---�-- ---
a Adapted from [7]. 
b Activity of reverse transcriptase released by lysis. 
* a and b represent separate experiments. 
system sufficiently so as to lead to lysis. In studies with EBV, 
approximately 25-fold more antibody was needed to trigger C­
dependent lysis than to produce full neutralization in conjunc­
tion with the C system [26]. 
A different situation may be presented by non-antibody­
dependent C-mediated lysis of retroviruses in that neutraliza­
tion probably proceeds by lysis [7,9] (Table lI). This reaction 
has now been observed with more than 20 different retroviruses 
from avian, feline, murine, and primate sources [6,9,20]. Retro­
virus neutralization is also distinguished by the fact that only 
primate C sources can neutralize and also lyse such viruses. It 
has been postulated that human C provides a defense mecha­
nism operative against retrovirus infection, since retroviruses 
are seldom isolated from humans and are frequently associated 
with malignancies in other species that lack the ability to 
destroy such viruses [7,9]. Further study is needed to assess the 
importance of C in retrovirus infections in primates. 
Antibody in high concentrations as well as the C system may 
eo at viruses with a blanket of protein that can be readily 
visualized in the electron microscope (Fig 2). Electron micro­
scopic studies carried out by Berry and Almeida some years 
ago showed that antibody produced a 300-A-thick layer of 
protein surrounding the virus, an event accompanied by signif­
icant viral neutralization [27]. In all probability the blanket of 
protein neutralizes the virus by interfering with the ability to 
attach and/or infect a potentially susceptible cell. Neutraliza­
tion by envelopment with Ab protein appears to require very 
high concentrations of protein not readily achievable in vivo. 
However, low levels of Ab bound to a virus readily activate the 
C system. As a consequence of C aetivation, multiple molecules 
of C protein are deposited on the viral surface. For example, in 
the studies of Berry and Almeida carried out with avian infec­
tious bronchitis virus, the thickneoss of the protein layer envel­
oping the virus increased to 700 A following the addition of C 
[27]. 
In many instances Ab alone fails to neutralize, but readily 
does so in conjunction with the C system. Studies with isolated 
C components now carried out with a number of viruses, 
including herpes simplex type 1, Epstein-Barr, int1uenza, 
equine arteritis, Newcastle disease, vesicular stomatitis, and 
vaccinia viruses, have shown that Codependent neutralization 
requires completion of the reaction sequence only through the 
C3 step [6,18,20] (Table III). Thus, even though these viruses 
are enveloped and can be lysed by the C system under certain 
experimental conditions, full neutralization occurs in the ab­
sence of lysis. Since no evidence for viral aggregation was 
obtained in those studies in which this possibility was exam­
ined, it is probable that such Codependent neutralization is the 
result of viral envelopment or blanketing with C protein. 
Thus there are three principal mechanisms by which Ab and/ 
or C can neutralize viruses. Of these, Ab-dependent and, in a 
few cases, Codependent viral aggregation appear to be uncom­
mon because of requirements for relatively high virus and Ab 
concentrations unlikely to be achieved in vivo and other phys­
ical and steric considerations. Complement-dependent lysis is 
also unlikely to be a biologically important mechanism of viral 
neutralization because a number of viruses are fully neutralized 
prior to the occurrence of, or in the absence of, lysis. Retrovi­
ruses, however, are probably an exception to this generalization, 
since they appear to be neutralized by lysis. The most important 
mechanism of viral neutralization appears to be that described 
by the terms envelopment or blanketing in a coating of protein. 
While it is presumed that the enveloping layer of Ab and/or C 
protein interferes with viral attachment to a susceptible cell, 
this has not been proven in any instance, and it could equally 
well be that attachment is unaffected, but later steps involving 
penetration or uncoating are impaired. 
CONSEQUENCES OF ANTIBODY AND 
COMPLEMENT INTERACTIONS WITH VIRUS­
INFECTED CELLS 
Human cells and cell lines infected with a number of RNA 
and DNA viruses are lysed by the C system in the presence of 
specific antibody [6,18,20]. The mechanisms involved in most 
of the early studies are unclear, however, since heterologous 
sources of cells, Ab, and C have generally been employed. In 
such systems, natural antibodies in the sera used as Ab and C 
sources react with the heterologous cells. Differences in C 
triggering by mixed sources of Ab and C and incompatibilities 
as well as enhanced reaetivity of C components from different 
species also complicate interpretation. 
In recent experiments carried out with entirely homologous 
systems, a number of different human cells infected with mul­
tiple RNA and DNA viruses, including measles, mumps, para­
int1uenza 1, 2, and 3, herpes simplex types 1 and 2, and 
influenza, have all been found to be lysed by human Ab and C 
T ABLE III. Complement-dependent neutralization of EB va 
Reactants added to purified EBV 
Cross-reacting IgG antibody 
Serum containing cross-reacting IgG anti­
body 
Purified Cl, C4, C2, C3 
Cross-reacting IgG antibody plus purified 
Cl, C4, C2 
Cross-reacting IgG antibody plus purified 
Cl, C4, C2, C3 
Cross-reacting IgG antibody plus PAP 
C8-depleted serum containing cross-react­
ing IgG antibody 
C8-depleted serum containing cross-react­
ing IgG antibody plus purified C8 
Heated C8-depleted serum containing 
cross-reacting IgG antibody --------- --- ----------- ------
a Adapted from [16]. 
Percent 
neutralization 
-2 
85 
4 
2 
69 
-7 
74 
70 
3 
--._-----
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TABLE IV. Altemative-pathway-mediated lysis of measles virus­
infected human cellsa 
--- - ------ ---- --- ---- ---- -----
Treatment of human serum 
containing specific antibody Percent lysis 
None 95 
Factor B-depleted 5 
Factor B-depleted plus purified factor B 95 
Factor D-depleted 7 
Factor D-depleted plus purified factor D 95 
C4-depleted 95 
C2-deficient 95 
a Adapted from [21]. 
[14,19,20]. In each case, lysis has been found to require IgG 
antibody and to be exclusively mediated by the alternative C 
pathway in conjunction with the membrane attack pathway. 
Multiple approaches have been used to prove that lysis proceeds 
by the alternative pathway. These included showing that lysis 
was sensitive to dilution and required magnesium but not 
calcium. Human sera lacking classical-pathway components 
sustained lysis, while sera depleted of alternative-pathway com­
ponents were inactive in this regard (Table IV). The lines of 
evidence documenting the alternative-pathway requirement 
have culminated in the demonstration that mixtures of the six 
purified proteins of the alternative pathway and the five pro­
teins of the membrane attack pathway at physiologic concen­
trations are as active as serum in mediating the lysis of human 
cells infected with measles virus in the presence of human Ab 
[27]. 
A somewhat surprising finding was the absolute requirement 
for IgG antibody for alternative C-mediated lysis [19]. Further­
more, very large numbers of IgG molecules per cell were re­
quired to initiate C-mediated lysis. Nevertheless, there was a 
requirement for specific Ab, since sera lacking such Ab were 
devoid of this ability but acquired it following the addition of 
the appropriate specific antiviral antibody [19,20]. Acquisition 
of the ability to lyse cells infected with measles or mumps virus 
also correlated with the development of Ab following primary 
immunization with the appropriate virus. Unlike Ab-dependent 
activation of the classical pathway, the Fc portion of the 
immunoglobulin molecule was not needed, and F(ab')2 frag­
ments of the IgG antibody were as active as the intact molecule 
facilitating alternative-pathway-mediated lysis [19,20,28]. Spe­
cific Ab to either of the two external glycoproteins of measles 
virus was equivalently efficient in initiating alternative-path­
way-mediated lysis [28]. 
In addition to the absolute requirement for specific Ab, 
certain other features of this system are unusual. First, unlike 
many alternative-pathway lytic systems, virus-infected cells 
lysed rapidly with kinetics approximately comparable with 
alternative-pathway-mediated lysis of certain erythrocytes 
[21,28]. A second unusual feature of the virus-infected cell 
model system is the absolute requirement for properdin for 
lysis [14,21]. Properdin is not essential for the lysis of any 
other cell type, including nucleated cells, by the isolated cyto­
lytic alternative pathway. 
The mediation of lysis by the alternative pathway in con­
junction with the membrane attack pathway indicates that 
virus-infected cells, together with specific Ab, trigger the alter­
native pathway. However, studies of the activation step as 
distinct from the lytic reaction have shown that Ab and pro­
perdin are not needed for activation, but rather only for the 
lytic event [14]. Thus activation, as measured by C3b deposi­
tion, occurs in the absence of these proteins [14]. Although not 
needed for initiation, the rate of alternative-pathway activa­
tion, but not the final extent, is markedly accelerated by IgG 
antibody as well as by properdin when present together with 
IgG. A similar pattern has also been observed for IgG in other 
IgG-potentiated alternative-pathway activation and lytic reac-
Vol. 83, No.1 Supplement 
tions [6,29,30]. The nature of the initial activation reaction and 
the role of IgG and properdin in accelerating activation and 
permitting lysis are not understood. Since activation proceeds 
in the absence of antibody, it is likely that some structural 
alteration in the cell membrane or perhaps an exposed viral 
protein represents the activator. Since F(ab')2 but not Fab' 
fragments of antiviral Ab facilitate lysis, redistribution of viral 
polypeptides on the membrane is probably required for lysis. 
Whether this creates or exposes additional activation sites or 
exposes portions of the lipoprotein envelope into which the 
C5b-9 complex moves remains to be determined. Alternatively 
or in addition, multivalent antibody-induced patching of the 
viral glycoproteins by antibody would cluster any attached C3b 
molecules, which would in turn facilitate properdin recruitment 
[31]. Properdin binding would stabilize the C3- and C5-cleaving 
enzymes, thereby facilitating the formation of additional C5b-
9. Since nucleated cells are normally quite resistant to C­
mediated lysis, the IgG and properdin requirements may relate 
to their ability to enhance activation of the late reacting C 
components. 
Although the classical complement pathway is triggered by 
virus-infected cells incubated with homologous Ab and C 
[19,22], in only one system has this pathway been found to 
mediate lysis [32]. The reasons for the failure of the classical 
pathway to produce lysis of cells infected with the numerous 
RNA and DNA viruses listed above in the presence of human 
IgG antibody are obscure, especially since this pathway, to­
gether with heterologous IgG antibody, readily lyses cells in­
fected with the same viruses. 
CONCLUSIONS 
Immune defenses against viral infections are complex and 
include several types of preexisting or natural immunity. Nat­
ural humoral defense mechanisms include C, which may be 
directly triggered by certain viruses and virus-infected cells in 
the absence of Ab and natural or cross-reacting Ab that com­
bines with the virus or virus-infected cell. Natural cellular 
immunity is represented by the actions of natural killer cells. 
On second contact with a virus, potent humoral and cellular 
immune responses serve to prevent and/or restrict viral infec­
tion. The humoral response includes the actions of Ab and the 
C system, while cellular immune responses include T-cell cy­
totoxicity and ADCC. These humoral and cellular mechanisms 
operate in synergy to inactive viruses, to prevent maturation 
and release of virus from infected cells, and to restrict the 
dissemination of virus infections. 
In addition to such direct effects of Ab and C on the virus 
and virus-infected cells, the C system has the ability to induce 
an acute inflammatory response in the vicinity of the activator. 
Thus it can alter vessel permeability and produce edema, induce 
changes in smooth-muscle contractility, stimulate the influx of 
leukocytes, and facilitate phagocytosis and the release of sec­
ondary mediators. Such inflammatory responses occurring in 
tissues as a result of C activation by viruses and virus-infected 
cells would restrict the spread of infection and facilitate de­
struction of the infectious agent. It is likely also that the 
attempts of the host to deal with the virus infection damage 
normal tissues in the vicinity of the acute inflammatory re­
sponse. In fact, a number of the systemic systems characteristic 
of viral infections may well result from complement-dependent 
release of histamine, other mediators, and pyrogens, as well as 
from stimulation of the cyclooxygenase and lip oxygenase path­
ways of arachidonic acid metabolism. 
Despite the existence of these forms of natura� and induced 
immunity and associated processes that would appear to be 
able to readily control viral infections, viral diseases are com­
mon. In addition, tissue damage in viral diseases may result 
not from the destructive actions of the virus, but from the 
overzealous attempts of the host to eliminate the viruses and 
the virus-infected cells. Such actions frequently produce dam-
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age to normal tissue and may be responsible for certain features 
of the viral disease. Important goals of contemporary viral 
immunology and immunopathology are the understanding, on 
a molecular basis, of these processes and of the types, effective­
ness, and interrelationships of host defenses against viral in­
fection. 
We wish to thank Ms. Bonnie Weier for her assistance in the 
preparation of this manuscript. 
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